|
G |
Abl1 |
ABL proto-oncogene 1, non-receptor tyrosine kinase |
multiple interactions decreases activity decreases phosphorylation |
ISO |
ponatinib inhibits the reaction [ABL1 protein mutant form results in increased phosphorylation of ABL1 protein mutant form]; ponatinib inhibits the reaction [ABL1 protein mutant form results in increased phosphorylation of CRKL protein]; ponatinib inhibits the reaction [ABL1 protein results in increased phosphorylation of ABL1 protein] ponatinib analog results in decreased activity of ABL1 protein; ponatinib analog results in decreased activity of ABL1 protein mutant form; ponatinib results in decreased activity of ABL1 protein; ponatinib results in decreased activity of ABL1 protein mutant form ponatinib results in decreased phosphorylation of ABL1 protein; ponatinib results in decreased phosphorylation of ABL1 protein mutant form |
CTD |
PMID:19878872 PMID:20513156 PMID:21561767 PMID:22781593 PMID:25304212 |
|
NCBI chr 3:14,979,853...15,083,065
Ensembl chr 3:14,979,853...15,083,065
|
|
G |
Abl2 |
ABL proto-oncogene 2, non-receptor tyrosine kinase |
decreases activity |
ISO |
ponatinib results in decreased activity of ABL2 protein |
CTD |
PMID:19878872 |
|
NCBI chr13:68,673,702...68,770,846
Ensembl chr13:68,673,722...68,839,742
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases phosphorylation |
ISO |
(+)-JQ1 compound promotes the reaction [ponatinib results in decreased phosphorylation of AKT1 protein]; ponatinib promotes the reaction [(+)-JQ1 compound results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:25053825 PMID:25304212 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
ISO |
ponatinib results in increased expression of BAX mRNA [gossypol acetic acid results in increased abundance of Gossypol] promotes the reaction [ponatinib results in increased expression of BAX mRNA] |
CTD |
PMID:34699866 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
ISO |
(+)-JQ1 compound promotes the reaction [ponatinib results in decreased expression of BCL2 protein]; ponatinib promotes the reaction [(+)-JQ1 compound results in decreased expression of BCL2 protein] ponatinib results in decreased expression of BCL2 mRNA [gossypol acetic acid results in increased abundance of Gossypol] promotes the reaction [ponatinib results in decreased expression of BCL2 mRNA]; ponatinib promotes the reaction [[gossypol acetic acid results in increased abundance of Gossypol] which results in decreased expression of BCL2 mRNA] |
CTD |
PMID:25053825 PMID:34699866 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
multiple interactions increases expression |
ISO |
(+)-JQ1 compound promotes the reaction [ponatinib results in increased expression of BCL2L11 protein]; ponatinib promotes the reaction [(+)-JQ1 compound results in increased expression of BCL2L11 protein] |
CTD |
PMID:25053825 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Bcr |
BCR activator of RhoGEF and GTPase |
decreases phosphorylation |
ISO |
ponatinib results in decreased phosphorylation of BCR protein mutant form |
CTD |
PMID:19878872 |
|
NCBI chr20:13,469,325...13,596,942
Ensembl chr20:13,471,668...13,597,016
|
|
G |
Blk |
BLK proto-oncogene, Src family tyrosine kinase |
decreases activity |
ISO |
ponatinib results in decreased activity of BLK protein |
CTD |
PMID:19878872 |
|
NCBI chr15:37,626,746...37,665,053
Ensembl chr15:37,627,039...37,665,031
|
|
G |
Bmx |
BMX non-receptor tyrosine kinase |
decreases activity |
ISO |
ponatinib results in decreased activity of BMX protein |
CTD |
PMID:19878872 |
|
NCBI chr X:30,227,251...30,290,015
Ensembl chr X:30,227,251...30,289,993
|
|
G |
Braf |
B-Raf proto-oncogene, serine/threonine kinase |
decreases activity |
ISO |
ponatinib analog results in decreased activity of BRAF protein; ponatinib analog results in decreased activity of BRAF protein mutant form |
CTD |
PMID:21561767 |
|
NCBI chr 4:68,375,484...68,510,652
Ensembl chr 4:68,384,649...68,510,463
|
|
G |
Casp3 |
caspase 3 |
increases cleavage |
ISO |
ponatinib results in increased cleavage of CASP3 protein |
CTD |
PMID:29341879 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases expression |
ISO |
[gossypol acetic acid results in increased abundance of Gossypol] promotes the reaction [ponatinib results in increased expression of CASP9 protein]; ponatinib promotes the reaction [[gossypol acetic acid results in increased abundance of Gossypol] which results in increased expression of CASP9 protein] |
CTD |
PMID:34699866 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions increases activity |
ISO |
[gossypol acetic acid results in increased abundance of Gossypol] promotes the reaction [ponatinib results in increased activity of CAT protein]; ponatinib promotes the reaction [[gossypol acetic acid results in increased abundance of Gossypol] which results in increased activity of CAT protein] |
CTD |
PMID:34699866 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
multiple interactions decreases expression |
ISO |
(+)-JQ1 compound promotes the reaction [ponatinib results in decreased expression of CDK4 protein]; ponatinib promotes the reaction [(+)-JQ1 compound results in decreased expression of CDK4 protein] |
CTD |
PMID:25053825 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
multiple interactions decreases expression |
ISO |
(+)-JQ1 compound promotes the reaction [ponatinib results in decreased expression of CDK6 protein]; ponatinib promotes the reaction [(+)-JQ1 compound results in decreased expression of CDK6 protein] |
CTD |
PMID:25053825 |
|
NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO |
(+)-JQ1 compound promotes the reaction [ponatinib results in increased expression of CDKN1A protein]; ponatinib promotes the reaction [(+)-JQ1 compound results in increased expression of CDKN1A protein] |
CTD |
PMID:25053825 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Crkl |
CRK like proto-oncogene, adaptor protein |
multiple interactions decreases phosphorylation |
ISO |
ponatinib inhibits the reaction [ABL1 protein mutant form results in increased phosphorylation of CRKL protein] ponatinib results in decreased phosphorylation of CRKL protein |
CTD |
PMID:19878872 PMID:25304212 |
|
NCBI chr11:83,528,788...83,563,214
Ensembl chr11:83,526,530...83,563,238
|
|
G |
Csf1r |
colony stimulating factor 1 receptor |
decreases activity |
ISO |
ponatinib analog results in decreased activity of CSF1R protein; ponatinib results in decreased activity of CSF1R protein |
CTD |
PMID:19878872 PMID:21561767 |
|
NCBI chr18:54,546,673...54,590,418
Ensembl chr18:54,546,659...54,590,415
|
|
G |
Csk |
C-terminal Src kinase |
decreases activity |
ISO |
ponatinib results in decreased activity of CSK protein |
CTD |
PMID:19878872 |
|
NCBI chr 8:58,029,748...58,048,742
Ensembl chr 8:58,029,749...58,048,292
|
|
G |
Ddr1 |
discoidin domain receptor tyrosine kinase 1 |
decreases phosphorylation |
ISO |
ponatinib inhibits the reaction [collagen increases autophosphorylation of DDR1 in U2OS cells] |
RGD |
PMID:24768818 |
RGD:151347549 |
NCBI chr20:3,042,494...3,064,442
Ensembl chr20:3,044,320...3,064,468
|
|
G |
Ddr2 |
discoidin domain receptor tyrosine kinase 2 |
decreases activity |
ISO |
ponatinib results in decreased activity of DDR2 protein |
CTD |
PMID:19878872 |
|
NCBI chr13:82,193,623...82,318,229
Ensembl chr13:82,195,463...82,317,363
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases activity |
ISO |
ponatinib results in decreased activity of EGFR protein mutant form |
CTD |
PMID:19878872 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Epha1 |
Eph receptor A1 |
decreases activity |
ISO |
ponatinib results in decreased activity of EPHA1 protein |
CTD |
PMID:19878872 |
|
NCBI chr 4:71,246,409...71,260,920
Ensembl chr 4:71,246,409...71,260,846
|
|
G |
Epha2 |
Eph receptor A2 |
decreases activity |
ISO |
ponatinib analog results in decreased activity of EPHA2 protein; ponatinib results in decreased activity of EPHA2 protein |
CTD |
PMID:19878872 PMID:21561767 |
|
NCBI chr 5:153,605,644...153,634,115
Ensembl chr 5:153,605,644...153,634,117
|
|
G |
Epha3 |
Eph receptor A3 |
decreases activity |
ISO |
ponatinib analog results in decreased activity of EPHA3 protein; ponatinib results in decreased activity of EPHA3 protein |
CTD |
PMID:19878872 PMID:21561767 |
|
NCBI chr11:1,138,485...1,474,102
Ensembl chr11:1,140,985...1,473,900
|
|
G |
Epha4 |
Eph receptor A4 |
decreases activity |
ISO |
ponatinib results in decreased activity of EPHA4 protein |
CTD |
PMID:19878872 |
|
NCBI chr 9:78,815,460...78,958,139
Ensembl chr 9:78,815,460...78,958,139
|
|
G |
Epha5 |
EPH receptor A5 |
decreases activity |
ISO |
ponatinib results in decreased activity of EPHA5 protein |
CTD |
PMID:19878872 |
|
NCBI chr14:23,653,393...24,020,129
Ensembl chr14:23,653,393...24,017,317
|
|
G |
Epha7 |
Eph receptor A7 |
decreases activity |
ISO |
ponatinib analog results in decreased activity of EPHA7 protein; ponatinib results in decreased activity of EPHA7 protein |
CTD |
PMID:19878872 PMID:21561767 |
|
NCBI chr 5:42,975,353...43,128,703
Ensembl chr 5:42,975,405...43,127,112
|
|
G |
Epha8 |
Eph receptor A8 |
decreases activity |
ISO |
ponatinib results in decreased activity of EPHA8 protein |
CTD |
PMID:19878872 |
|
NCBI chr 5:149,166,107...149,193,515
Ensembl chr 5:149,166,697...149,193,399
|
|
G |
Ephb1 |
Eph receptor B1 |
decreases activity |
ISO |
ponatinib results in decreased activity of EPHB1 protein |
CTD |
PMID:19878872 |
|
NCBI chr 8:102,507,549...102,944,839
Ensembl chr 8:102,507,549...102,944,839
|
|
G |
Ephb2 |
Eph receptor B2 |
decreases activity |
ISO |
ponatinib results in decreased activity of EPHB2 protein |
CTD |
PMID:19878872 |
|
NCBI chr 5:148,889,574...149,077,027
Ensembl chr 5:148,897,246...149,077,059
|
|
G |
Ephb3 |
Eph receptor B3 |
decreases activity |
ISO |
ponatinib results in decreased activity of EPHB3 protein |
CTD |
PMID:19878872 |
|
NCBI chr11:79,840,668...79,859,345
Ensembl chr11:79,840,668...79,859,370
|
|
G |
Ephb4 |
EPH receptor B4 |
decreases activity |
ISO |
ponatinib results in decreased activity of EPHB4 protein |
CTD |
PMID:19878872 |
|
NCBI chr12:19,326,411...19,351,667
Ensembl chr12:19,326,427...19,351,314
|
|
G |
Erbb4 |
erb-b2 receptor tyrosine kinase 4 |
decreases activity |
ISO |
ponatinib results in decreased activity of ERBB4 protein |
CTD |
PMID:19878872 |
|
NCBI chr 9:69,523,733...70,596,743
Ensembl chr 9:69,531,481...70,596,595
|
|
G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
decreases activity decreases phosphorylation |
ISO |
ponatinib analog results in decreased activity of FGFR1 protein; ponatinib results in decreased activity of FGFR1 protein; ponatinib results in decreased activity of FGFR1 protein mutant form ponatinib results in decreased phosphorylation of FGFR1 protein mutant form |
CTD |
PMID:19878872 PMID:21482694 PMID:21561767 PMID:22875613 |
|
NCBI chr16:66,491,930...66,547,161
Ensembl chr16:66,494,042...66,547,350
|
|
G |
Fgfr2 |
fibroblast growth factor receptor 2 |
decreases activity |
ISO |
ponatinib analog results in decreased activity of FGFR2 protein; ponatinib results in decreased activity of FGFR2 protein; ponatinib results in decreased activity of FGFR2 protein mutant form |
CTD |
PMID:19878872 PMID:21561767 |
|
NCBI chr 1:184,745,418...184,850,655
Ensembl chr 1:184,745,420...184,850,626
|
|
G |
Fgfr3 |
fibroblast growth factor receptor 3 |
decreases activity |
ISO |
ponatinib analog results in decreased activity of FGFR3 protein; ponatinib results in decreased activity of FGFR3 protein |
CTD |
PMID:19878872 PMID:21561767 |
|
NCBI chr14:76,987,242...77,002,671
Ensembl chr14:76,987,993...77,003,341
|
|
G |
Fgfr4 |
fibroblast growth factor receptor 4 |
decreases activity multiple interactions decreases expression |
ISO |
ponatinib analog results in decreased activity of FGFR4 protein; ponatinib results in decreased activity of FGFR4 protein [gossypol acetic acid results in increased abundance of Gossypol] promotes the reaction [ponatinib results in decreased expression of FGFR4 mRNA]; ponatinib promotes the reaction [[gossypol acetic acid results in increased abundance of Gossypol] which results in decreased expression of FGFR4 mRNA] |
CTD |
PMID:19878872 PMID:21561767 PMID:34699866 |
|
NCBI chr17:9,461,541...9,476,268
Ensembl chr17:9,461,547...9,476,242
|
|
G |
Fgr |
FGR proto-oncogene, Src family tyrosine kinase |
decreases activity |
ISO |
ponatinib results in decreased activity of FGR protein |
CTD |
PMID:19878872 |
|
NCBI chr 5:145,189,814...145,219,571
Ensembl chr 5:145,189,841...145,217,326
|
|
G |
Flt1 |
Fms related receptor tyrosine kinase 1 |
decreases activity |
ISO |
ponatinib analog results in decreased activity of FLT1 protein; ponatinib results in decreased activity of FLT1 protein |
CTD |
PMID:19878872 PMID:21561767 |
|
NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626
|
|
G |
Flt3 |
Fms related receptor tyrosine kinase 3 |
decreases activity multiple interactions decreases phosphorylation |
ISO |
ponatinib analog results in decreased activity of FLT3 protein; ponatinib results in decreased activity of FLT3 protein; ponatinib results in decreased activity of FLT3 protein mutant form ponatinib inhibits the reaction [FLT3 protein mutant form results in increased phosphorylation of FLT3 protein mutant form] ponatinib results in decreased phosphorylation of FLT3 protein mutant form |
CTD |
PMID:19878872 PMID:21482694 PMID:21561767 PMID:22409268 |
|
NCBI chr12:7,623,930...7,699,474
Ensembl chr12:7,623,930...7,699,474
|
|
G |
Flt4 |
Fms related receptor tyrosine kinase 4 |
decreases activity |
ISO |
ponatinib analog results in decreased activity of FLT4 protein; ponatinib results in decreased activity of FLT4 protein |
CTD |
PMID:19878872 PMID:21561767 |
|
NCBI chr10:33,913,725...33,954,770
Ensembl chr10:33,913,608...33,954,770
|
|
G |
Frk |
fyn-related Src family tyrosine kinase |
decreases activity |
ISO |
ponatinib results in decreased activity of FRK protein |
CTD |
PMID:19878872 |
|
NCBI chr20:38,265,416...38,371,038
Ensembl chr20:38,265,280...38,371,114
|
|
G |
Fyn |
FYN proto-oncogene, Src family tyrosine kinase |
decreases activity |
ISO |
ponatinib results in decreased activity of FYN protein |
CTD |
PMID:19878872 |
|
NCBI chr20:42,767,733...42,960,903
Ensembl chr20:42,766,369...42,959,911
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
increases secretion |
ISO |
ponatinib results in increased secretion of GPT protein |
CTD |
PMID:29655783 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Hck |
HCK proto-oncogene, Src family tyrosine kinase |
decreases activity |
ISO |
ponatinib results in decreased activity of HCK protein |
CTD |
PMID:19878872 |
|
NCBI chr 3:141,571,587...141,614,696
Ensembl chr 3:141,571,587...141,614,693
|
|
G |
Jak1 |
Janus kinase 1 |
decreases activity |
ISO |
ponatinib results in decreased activity of JAK1 protein |
CTD |
PMID:19878872 |
|
NCBI chr 5:115,780,248...115,888,841
Ensembl chr 5:115,780,248...115,888,926
|
|
G |
Jak2 |
Janus kinase 2 |
decreases activity |
ISO |
ponatinib results in decreased activity of JAK2 protein |
CTD |
PMID:19878872 |
|
NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Jak3 |
Janus kinase 3 |
decreases activity |
ISO |
ponatinib results in decreased activity of JAK3 protein |
CTD |
PMID:19878872 |
|
NCBI chr16:18,386,330...18,398,542
Ensembl chr16:18,386,405...18,398,536
|
|
G |
Kdr |
kinase insert domain receptor |
decreases activity |
ISO |
ponatinib analog results in decreased activity of KDR protein; ponatinib results in decreased activity of KDR protein |
CTD |
PMID:19878872 PMID:21561767 |
|
NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
|
|
G |
Kit |
KIT proto-oncogene receptor tyrosine kinase |
decreases activity decreases phosphorylation |
ISO |
ponatinib results in decreased activity of KIT protein; ponatinib results in decreased activity of KIT protein mutant form ponatinib results in decreased phosphorylation of KIT protein mutant form |
CTD |
PMID:19878872 PMID:21482694 |
|
NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652
|
|
G |
Lck |
LCK proto-oncogene, Src family tyrosine kinase |
decreases activity |
ISO |
ponatinib results in decreased activity of LCK protein |
CTD |
PMID:19878872 |
|
NCBI chr 5:141,888,318...141,916,945
Ensembl chr 5:141,888,326...141,903,794
|
|
G |
Lmna |
lamin A/C |
increases cleavage |
ISO |
ponatinib results in increased cleavage of LMNA protein |
CTD |
PMID:22875613 |
|
NCBI chr 2:173,939,751...173,960,423
Ensembl chr 2:173,939,751...173,960,423
|
|
G |
Lyn |
LYN proto-oncogene, Src family tyrosine kinase |
decreases activity |
ISO |
ponatinib results in decreased activity of LYN protein |
CTD |
PMID:19878872 |
|
NCBI chr 5:16,639,512...16,755,501
Ensembl chr 5:16,639,466...16,756,868
|
|
G |
Map1lc3a |
microtubule-associated protein 1 light chain 3 alpha |
increases lipidation |
ISO |
ponatinib results in increased lipidation of MAP1LC3A protein |
CTD |
PMID:29341879 |
|
NCBI chr 3:143,783,024...143,784,670
Ensembl chr 3:143,783,024...143,784,670
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions decreases phosphorylation |
ISO |
(+)-JQ1 compound promotes the reaction [ponatinib results in decreased phosphorylation of MAPK1 protein]; ponatinib promotes the reaction [(+)-JQ1 compound results in decreased phosphorylation of MAPK1 protein] |
CTD |
PMID:22409268 PMID:22875613 PMID:25053825 PMID:25304212 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions decreases phosphorylation |
ISO |
(+)-JQ1 compound promotes the reaction [ponatinib results in decreased phosphorylation of MAPK3 protein]; ponatinib promotes the reaction [(+)-JQ1 compound results in decreased phosphorylation of MAPK3 protein] |
CTD |
PMID:22409268 PMID:22875613 PMID:25053825 PMID:25304212 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
decreases expression |
ISO |
ponatinib results in decreased expression of MCL1 protein |
CTD |
PMID:22409268 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions decreases expression |
ISO |
(+)-JQ1 compound promotes the reaction [ponatinib results in decreased expression of MYC protein]; ponatinib promotes the reaction [(+)-JQ1 compound results in decreased expression of MYC protein] |
CTD |
PMID:25053825 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Ntrk1 |
neurotrophic receptor tyrosine kinase 1 |
decreases activity |
ISO |
ponatinib results in decreased activity of NTRK1 protein |
CTD |
PMID:19878872 |
|
NCBI chr 2:173,236,961...173,253,806
Ensembl chr 2:173,236,963...173,253,770
|
|
G |
Ntrk2 |
neurotrophic receptor tyrosine kinase 2 |
decreases activity |
ISO |
ponatinib results in decreased activity of NTRK2 protein |
CTD |
PMID:19878872 |
|
NCBI chr17:5,558,992...5,870,299
Ensembl chr17:5,559,043...5,869,136
|
|
G |
Ntrk3 |
neurotrophic receptor tyrosine kinase 3 |
decreases activity |
ISO |
ponatinib results in decreased activity of NTRK3 protein |
CTD |
PMID:19878872 |
|
NCBI chr 1:132,116,472...132,503,849
Ensembl chr 1:132,132,849...132,503,286
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
(+)-JQ1 compound promotes the reaction [ponatinib results in increased cleavage of PARP1 protein]; ponatinib promotes the reaction [(+)-JQ1 compound results in increased cleavage of PARP1 protein] |
CTD |
PMID:21482694 PMID:22875613 PMID:25053825 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pdgfra |
platelet derived growth factor receptor alpha |
decreases activity decreases phosphorylation |
ISO |
ponatinib analog results in decreased activity of PDGFRA protein; ponatinib results in decreased activity of PDGFRA protein; ponatinib results in decreased activity of PDGFRA protein mutant form ponatinib results in decreased phosphorylation of PDGFRA protein mutant form |
CTD |
PMID:19878872 PMID:21482694 PMID:21561767 |
|
NCBI chr14:33,005,838...33,054,347
Ensembl chr14:33,005,839...33,054,335
|
|
G |
Pdgfrb |
platelet derived growth factor receptor beta |
decreases activity |
ISO |
ponatinib analog results in decreased activity of PDGFRB protein; ponatinib results in decreased activity of PDGFRB protein |
CTD |
PMID:19878872 PMID:21561767 |
|
NCBI chr18:54,499,962...54,538,840
Ensembl chr18:54,499,964...54,538,843
|
|
G |
Ptk2b |
protein tyrosine kinase 2 beta |
decreases activity |
ISO |
ponatinib results in decreased activity of PTK2B protein |
CTD |
PMID:19878872 |
|
NCBI chr15:40,360,722...40,481,235
Ensembl chr15:40,360,723...40,481,282
|
|
G |
Ptk6 |
protein tyrosine kinase 6 |
decreases activity |
ISO |
ponatinib results in decreased activity of PTK6 protein |
CTD |
PMID:19878872 |
|
NCBI chr 3:168,307,073...168,315,664
Ensembl chr 3:168,307,073...168,315,664
|
|
G |
Ret |
ret proto-oncogene |
decreases activity |
ISO |
ponatinib analog results in decreased activity of RET protein; ponatinib results in decreased activity of RET protein; ponatinib results in decreased activity of RET protein mutant form |
CTD |
PMID:19878872 PMID:21561767 |
|
NCBI chr 4:151,325,969...151,368,176
Ensembl chr 4:151,326,431...151,368,176
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
decreases activity |
ISO |
ponatinib analog results in decreased activity of SRC protein; ponatinib results in decreased activity of SRC protein |
CTD |
PMID:19878872 PMID:21561767 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Stat5a |
signal transducer and activator of transcription 5A |
multiple interactions decreases phosphorylation |
ISO |
ponatinib promotes the reaction [(+)-JQ1 compound results in decreased phosphorylation of STAT5A protein] ponatinib results in decreased phosphorylation of STAT5A protein |
CTD |
PMID:22875613 PMID:25053825 |
|
NCBI chr10:85,785,537...85,809,869
Ensembl chr10:85,785,537...85,809,866
|
|
G |
Stat5b |
signal transducer and activator of transcription 5B |
multiple interactions |
ISO |
ponatinib promotes the reaction [(+)-JQ1 compound results in decreased phosphorylation of STAT5B protein] |
CTD |
PMID:25053825 |
|
NCBI chr10:85,704,841...85,775,856
Ensembl chr10:85,705,670...85,775,668
|
|
G |
Tek |
TEK receptor tyrosine kinase |
decreases activity |
ISO |
ponatinib analog results in decreased activity of TEK protein; ponatinib results in decreased activity of TEK protein |
CTD |
PMID:19878872 PMID:21561767 |
|
NCBI chr 5:109,607,077...109,733,805
Ensembl chr 5:109,607,077...109,733,804
|
|
G |
Tnni3 |
troponin I3, cardiac type |
increases secretion |
ISO |
ponatinib results in increased secretion of TNNI3 protein |
CTD |
PMID:25304212 |
|
NCBI chr 1:69,299,900...69,303,582
Ensembl chr 1:69,299,900...69,303,580
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases expression |
ISO |
[gossypol acetic acid results in increased abundance of Gossypol] promotes the reaction [ponatinib results in increased expression of TRP53 protein]; ponatinib promotes the reaction [[gossypol acetic acid results in increased abundance of Gossypol] which results in increased expression of TRP53 protein] |
CTD |
PMID:34699866 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tyk2 |
tyrosine kinase 2 |
decreases activity |
ISO |
ponatinib results in decreased activity of TYK2 protein |
CTD |
PMID:19878872 |
|
NCBI chr 8:19,641,881...19,667,157
Ensembl chr 8:19,641,884...19,667,044
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
decreases activity |
ISO |
ponatinib results in decreased activity of UGT1A1 protein |
CTD |
PMID:37597759 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
decreases activity |
ISO |
ponatinib results in decreased activity of UGT1A9 protein |
CTD |
PMID:37597759 |
|
NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions decreases expression |
ISO |
[gossypol acetic acid results in increased abundance of Gossypol] promotes the reaction [ponatinib results in decreased expression of VEGFA protein]; ponatinib promotes the reaction [[gossypol acetic acid results in increased abundance of Gossypol] which results in decreased expression of VEGFA protein] |
CTD |
PMID:34699866 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Yes1 |
YES proto-oncogene 1, Src family tyrosine kinase |
decreases activity |
ISO |
ponatinib results in decreased activity of YES1 protein |
CTD |
PMID:19878872 |
|
NCBI chr 9:113,200,256...113,275,942
Ensembl chr 9:113,200,256...113,299,837
|
|